Skip to main content
Erschienen in: Annals of Hematology 10/2013

01.10.2013 | Original Article

The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes

verfasst von: Bin Fu, Chi Young Ok, Maitrayee Goswami, Wei Xei, Jesse M. Jaso, Tariq Muzzafar, Carlos Bueso-Ramos, Srdan Verstovsek, Guillermo Garcia-Manero, L. Jeffrey Medeiros, Sa A. Wang

Erschienen in: Annals of Hematology | Ausgabe 10/2013

Einloggen, um Zugang zu erhalten

Abstract

The presence of moderate to severe bone marrow (BM) fibrosis has been shown to be an adverse feature in patients with primary myelodysplastic syndromes (MDS). However, the clinical importance of BM fibrosis is not clear in therapy-related MDS. We retrieved all therapy-related MDS (t-MDS) cases (n = 266) diagnosed at our hospital over a 10-year period (2003–2012). Reticulin and trichrome stains were performed in cases in which BM fibrosis was suspected on initial evaluation of hematoxylin and eosin-stained slide. BM fibrosis was graded according to European consensus guidelines, and a score of MF2/MF3 was defined as moderate/severe fibrosis. Moderate/severe BM fibrosis was found in 47 (17 %) patients. Compared to 219 patients with no/mild BM fibrosis, the patients with moderate/severe fibrosis presented with severer thrombocytopenia (p = 0.039) and higher numbers of circulating blasts (p = 0.051) but with similar degrees of anemia and neutropenia, transfusion requirements, and similar incidences of hepatosplenomegaly and constitutional symptoms. Histological examination revealed a comparable BM cellularity and BM blast percentage, but markedly increased megakaryocytes (p < 0.001) in the fibrotic group. Although the risk distribution of cytogenetic data was similar according to the New Comprehensive Cytogenetic Scoring criteria, −5 and −17 were more frequently observed in t-MDS with moderate/severe BM fibrosis (p = 0.031 and p = 0.043, respectively). With a median follow-up of 11.5 months, patients with moderate/severe BM fibrosis showed a similar risk of acute myeloid leukemia transformation and a comparable overall survival in univariate and multivariate analyses. Moderate/severe BM fibrosis in patients with t-MDS is associated with certain clinicopathological and genetic features. However, unlike the situation in patients with primary MDS, moderate/severe BM fibrosis does not add additional risk to patients with therapy-related MDS.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Kvasnicka HM, Thiele J, Schmitt-Graeff A, Diehl V, Zankovich R, Niederle N, Leder LD, Schaefer HE (2001) Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial. J Clin Oncol 19(12):2994–3009PubMed Kvasnicka HM, Thiele J, Schmitt-Graeff A, Diehl V, Zankovich R, Niederle N, Leder LD, Schaefer HE (2001) Bone marrow features improve prognostic efficiency in multivariate risk classification of chronic-phase Ph(1+) chronic myelogenous leukemia: a multicenter trial. J Clin Oncol 19(12):2994–3009PubMed
4.
Zurück zum Zitat Thiele J, Kvasnicka HM (2006) Grade of bone marrow fibrosis is associated with relevant hematological findings—a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol 85(4):226–232. doi:10.1007/s00277-005-0042-8 PubMedCrossRef Thiele J, Kvasnicka HM (2006) Grade of bone marrow fibrosis is associated with relevant hematological findings—a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol 85(4):226–232. doi:10.​1007/​s00277-005-0042-8 PubMedCrossRef
5.
Zurück zum Zitat Vener C, Fracchiolla NS, Gianelli U, Calori R, Radaelli F, Iurlo A, Caberlon S, Gerli G, Boiocchi L, Deliliers GL (2008) Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood 111(4):1862–1865. doi:10.1182/blood-2007-09-112953 PubMedCrossRef Vener C, Fracchiolla NS, Gianelli U, Calori R, Radaelli F, Iurlo A, Caberlon S, Gerli G, Boiocchi L, Deliliers GL (2008) Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood 111(4):1862–1865. doi:10.​1182/​blood-2007-09-112953 PubMedCrossRef
6.
Zurück zum Zitat Gianelli U, Vener C, Bossi A, Cortinovis I, Iurlo A, Fracchiolla NS, Savi F, Moro A, Grifoni F, De Philippis C, Radice T, Bosari S, Lambertenghi Deliliers G, Cortelezzi A (2012) The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Modern pathology 25(9):1193–1202. doi:10.1038/modpathol.2012.87 PubMedCrossRef Gianelli U, Vener C, Bossi A, Cortinovis I, Iurlo A, Fracchiolla NS, Savi F, Moro A, Grifoni F, De Philippis C, Radice T, Bosari S, Lambertenghi Deliliers G, Cortelezzi A (2012) The European Consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Modern pathology 25(9):1193–1202. doi:10.​1038/​modpathol.​2012.​87 PubMedCrossRef
7.
Zurück zum Zitat Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937–951. doi:10.1182/blood-2009-03-209262 PubMedCrossRef Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114(5):937–951. doi:10.​1182/​blood-2009-03-209262 PubMedCrossRef
8.
Zurück zum Zitat Verhoef GE, De Wolf-Peeters C, Ferrant A, Deprez S, Meeus P, Stul M, Zachee P, Cassiman JJ, Van den Berghe H, Boogaerts MA (1991) Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. Ann Hematol 63(5):235–241PubMedCrossRef Verhoef GE, De Wolf-Peeters C, Ferrant A, Deprez S, Meeus P, Stul M, Zachee P, Cassiman JJ, Van den Berghe H, Boogaerts MA (1991) Myelodysplastic syndromes with bone marrow fibrosis: a myelodysplastic disorder with proliferative features. Ann Hematol 63(5):235–241PubMedCrossRef
10.
Zurück zum Zitat Buesche G, Teoman H, Wilczak W, Ganser A, Hecker H, Wilkens L, Gohring G, Schlegelberger B, Bock O, Georgii A, Kreipe H (2008) Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 22(2):313–322. doi:10.1038/sj.leu.2405030 PubMedCrossRef Buesche G, Teoman H, Wilczak W, Ganser A, Hecker H, Wilkens L, Gohring G, Schlegelberger B, Bock O, Georgii A, Kreipe H (2008) Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia 22(2):313–322. doi:10.​1038/​sj.​leu.​2405030 PubMedCrossRef
11.
Zurück zum Zitat Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, Passamonti F, Invernizzi R, Castello A, Magrini U, Lazzarino M, Cazzola M (2009) Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 27(5):754–762. doi:10.1200/JCO.2008.18.2246 PubMedCrossRef Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, Passamonti F, Invernizzi R, Castello A, Magrini U, Lazzarino M, Cazzola M (2009) Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 27(5):754–762. doi:10.​1200/​JCO.​2008.​18.​2246 PubMedCrossRef
12.
Zurück zum Zitat Kroger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R, Lim ZY, Onida F, Schmid C, Garderet L, Robin M, van Gelder M, Marks R, Symeonidis A, Kobbe G, de Witte T (2011) Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. Haematologica 96(2):291–297. doi:10.3324/haematol.2010.031229 PubMedCrossRef Kroger N, Zabelina T, van Biezen A, Brand R, Niederwieser D, Martino R, Lim ZY, Onida F, Schmid C, Garderet L, Robin M, van Gelder M, Marks R, Symeonidis A, Kobbe G, de Witte T (2011) Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis. Haematologica 96(2):291–297. doi:10.​3324/​haematol.​2010.​031229 PubMedCrossRef
13.
14.
Zurück zum Zitat Greco M, D’Alo F, Scardocci A, Criscuolo M, Fabiani E, Guidi F, Di Ruscio A, Migliara G, Pagano L, Fianchi L, Chiusolo P, Hohaus S, Leone G, Voso MT (2010) Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood cells, molecules & diseases 45(3):181–185. doi:10.1016/j.bcmd.2010.05.008 CrossRef Greco M, D’Alo F, Scardocci A, Criscuolo M, Fabiani E, Guidi F, Di Ruscio A, Migliara G, Pagano L, Fianchi L, Chiusolo P, Hohaus S, Leone G, Voso MT (2010) Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. Blood cells, molecules & diseases 45(3):181–185. doi:10.​1016/​j.​bcmd.​2010.​05.​008 CrossRef
15.
Zurück zum Zitat Li L, Li M, Sun C, Francisco L, Chakraborty S, Sabado M, McDonald T, Gyorffy J, Chang K, Wang S, Fan W, Li J, Zhao LP, Radich J, Forman S, Bhatia S, Bhatia R (2011) Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer cell 20(5):591–605. doi:10.1016/j.ccr.2011.09.011 PubMedCrossRef Li L, Li M, Sun C, Francisco L, Chakraborty S, Sabado M, McDonald T, Gyorffy J, Chang K, Wang S, Fan W, Li J, Zhao LP, Radich J, Forman S, Bhatia S, Bhatia R (2011) Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer cell 20(5):591–605. doi:10.​1016/​j.​ccr.​2011.​09.​011 PubMedCrossRef
16.
Zurück zum Zitat Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J (2005) Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 19(12):2232–2240. doi:10.1038/sj.leu.2404009 PubMedCrossRef Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J (2005) Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 19(12):2232–2240. doi:10.​1038/​sj.​leu.​2404009 PubMedCrossRef
17.
Zurück zum Zitat Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM, Larson RA, Vardiman JW (2007) Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol 127(2):197–205. doi:10.1309/NQ3PMV4U8YV39JWJ PubMedCrossRef Singh ZN, Huo D, Anastasi J, Smith SM, Karrison T, Le Beau MM, Larson RA, Vardiman JW (2007) Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant. Am J Clin Pathol 127(2):197–205. doi:10.​1309/​NQ3PMV4U8YV39JWJ​ PubMedCrossRef
18.
Zurück zum Zitat Vardiman JW, Arber DA, Brunning RD, Larson RA, Matutes E, Baumann I, Thiele J (eds) (2008) Therapy-related myeloid neoplasms. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC), vol 184, 4th edn. Elsevier, Lyon, pp 16–20 Vardiman JW, Arber DA, Brunning RD, Larson RA, Matutes E, Baumann I, Thiele J (eds) (2008) Therapy-related myeloid neoplasms. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC), vol 184, 4th edn. Elsevier, Lyon, pp 16–20
19.
Zurück zum Zitat Klyuchnikov E, Holler E, Bornhauser M, Kobbe G, Nagler A, Shimoni A, Konecke C, Wolschke C, Bacher U, Zander AR, Kroger N (2012) Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Br J Haematol. doi:10.1111/bjh.12013 PubMed Klyuchnikov E, Holler E, Bornhauser M, Kobbe G, Nagler A, Shimoni A, Konecke C, Wolschke C, Bacher U, Zander AR, Kroger N (2012) Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting. Br J Haematol. doi:10.​1111/​bjh.​12013 PubMed
20.
Zurück zum Zitat Quintas-Cardama AKH, Shan J, Jabbour E, Faderl S, Wierda WG, RavandiF KT, Wang SA, Pierce S, Kantarjian HM, Garcia-Manero G (2012) A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Blood 118(suppl 1):967 Quintas-Cardama AKH, Shan J, Jabbour E, Faderl S, Wierda WG, RavandiF KT, Wang SA, Pierce S, Kantarjian HM, Garcia-Manero G (2012) A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia. Blood 118(suppl 1):967
21.
Zurück zum Zitat Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90(8):1128–1132PubMed Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A (2005) European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90(8):1128–1132PubMed
22.
Zurück zum Zitat Khoury JD, Sen F, Abruzzo LV, Hayes K, Glassman A, Medeiros LJ (2003) Cytogenetic findings in blastoid mantle cell lymphoma. Hum Pathol 34(10):1022–1029PubMedCrossRef Khoury JD, Sen F, Abruzzo LV, Hayes K, Glassman A, Medeiros LJ (2003) Cytogenetic findings in blastoid mantle cell lymphoma. Hum Pathol 34(10):1022–1029PubMedCrossRef
23.
Zurück zum Zitat Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454–2465. doi:10.1182/blood-2012-03-420489 PubMedCrossRef Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454–2465. doi:10.​1182/​blood-2012-03-420489 PubMedCrossRef
24.
Zurück zum Zitat Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstocker M, Nosslinger T, Valent P, Giagounidis A, Aul C, Lubbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30(8):820–829. doi:10.1200/JCO.2011.35.6394 PubMedCrossRef Schanz J, Tuchler H, Sole F, Mallo M, Luno E, Cervera J, Granada I, Hildebrandt B, Slovak ML, Ohyashiki K, Steidl C, Fonatsch C, Pfeilstocker M, Nosslinger T, Valent P, Giagounidis A, Aul C, Lubbert M, Stauder R, Krieger O, Garcia-Manero G, Faderl S, Pierce S, Le Beau MM, Bennett JM, Greenberg P, Germing U, Haase D (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 30(8):820–829. doi:10.​1200/​JCO.​2011.​35.​6394 PubMedCrossRef
25.
Zurück zum Zitat Chen W, Konoplev S, Medeiros LJ, Koeppen H, Leventaki V, Vadhan-Raj S, Jones D, Kantarjian HM, Falini B, Bueso-Ramos CE (2009) Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. Cancer 115(23):5481–5489. doi:10.1002/cncr.24610 PubMedCrossRef Chen W, Konoplev S, Medeiros LJ, Koeppen H, Leventaki V, Vadhan-Raj S, Jones D, Kantarjian HM, Falini B, Bueso-Ramos CE (2009) Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. Cancer 115(23):5481–5489. doi:10.​1002/​cncr.​24610 PubMedCrossRef
26.
Zurück zum Zitat Millecker L, Lennon PA, Verstovsek S, Barkoh B, Galbincea J, Hu P, Chen SS, Jones D (2010) Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations. Cancer genetics and cytogenetics 197(1):1–7. doi:10.1016/j.cancergencyto.2009.10.014 PubMedCrossRef Millecker L, Lennon PA, Verstovsek S, Barkoh B, Galbincea J, Hu P, Chen SS, Jones D (2010) Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations. Cancer genetics and cytogenetics 197(1):1–7. doi:10.​1016/​j.​cancergencyto.​2009.​10.​014 PubMedCrossRef
27.
Zurück zum Zitat Gustafson SA, Lin P, Chen SS, Chen L, Abruzzo LV, Luthra R, Medeiros LJ, Wang SA (2009) Therapy-related acute myeloid leukemia with t (8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t (8;21)(q22;q22) but does not have a favorable outcome. Am J Clin Pathol 131(5):647–655. doi:10.1309/AJCP5ETHDXO6NCGZ PubMedCrossRef Gustafson SA, Lin P, Chen SS, Chen L, Abruzzo LV, Luthra R, Medeiros LJ, Wang SA (2009) Therapy-related acute myeloid leukemia with t (8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t (8;21)(q22;q22) but does not have a favorable outcome. Am J Clin Pathol 131(5):647–655. doi:10.​1309/​AJCP5ETHDXO6NCGZ​ PubMedCrossRef
29.
Zurück zum Zitat Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, Lu G, Wang S, Garcia-Manero G, Vadhan-Raj S, Hoehn D, Medeiros LJ, Yin CC (2012) Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer 118(11):2879–2888. doi:10.1002/cncr.26537 PubMedCrossRef Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, Lu G, Wang S, Garcia-Manero G, Vadhan-Raj S, Hoehn D, Medeiros LJ, Yin CC (2012) Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer 118(11):2879–2888. doi:10.​1002/​cncr.​26537 PubMedCrossRef
31.
Zurück zum Zitat Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A (2005) Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 105(3):973–977. doi:10.1182/blood-2004-07-2864 PubMedCrossRef Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A (2005) Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 105(3):973–977. doi:10.​1182/​blood-2004-07-2864 PubMedCrossRef
32.
Zurück zum Zitat Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E, Massa M, Rosti V, Campanelli R, Villani L, Viarengo G, Gattoni E, Gerli G, Specchia G, Tinelli C, Rambaldi A, Barbui T (2007) JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110(12):4030–4036. doi:10.1182/blood-2007-07-099184 PubMedCrossRef Barosi G, Bergamaschi G, Marchetti M, Vannucchi AM, Guglielmelli P, Antonioli E, Massa M, Rosti V, Campanelli R, Villani L, Viarengo G, Gattoni E, Gerli G, Specchia G, Tinelli C, Rambaldi A, Barbui T (2007) JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 110(12):4030–4036. doi:10.​1182/​blood-2007-07-099184 PubMedCrossRef
35.
Zurück zum Zitat Buhr T, Busche G, Choritz H, Langer F, Kreipe H (2003) Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol 119(1):152–158. doi:10.1309/PTVG-B3DX-B8A8-M7KD PubMedCrossRef Buhr T, Busche G, Choritz H, Langer F, Kreipe H (2003) Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol 119(1):152–158. doi:10.​1309/​PTVG-B3DX-B8A8-M7KD PubMedCrossRef
36.
Zurück zum Zitat Morel F, Le Bris MJ, Herry A, Morice P, De Braekeleer M (2003) Trisomy 15 as the sole abnormality in myelodysplastic syndromes: case report and review of the literature. Leukemia & lymphoma 44(3):549–551. doi:10.1080/1042819021000055084 CrossRef Morel F, Le Bris MJ, Herry A, Morice P, De Braekeleer M (2003) Trisomy 15 as the sole abnormality in myelodysplastic syndromes: case report and review of the literature. Leukemia & lymphoma 44(3):549–551. doi:10.​1080/​1042819021000055​084 CrossRef
Metadaten
Titel
The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes
verfasst von
Bin Fu
Chi Young Ok
Maitrayee Goswami
Wei Xei
Jesse M. Jaso
Tariq Muzzafar
Carlos Bueso-Ramos
Srdan Verstovsek
Guillermo Garcia-Manero
L. Jeffrey Medeiros
Sa A. Wang
Publikationsdatum
01.10.2013
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 10/2013
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1776-3

Weitere Artikel der Ausgabe 10/2013

Annals of Hematology 10/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.